Plus Therapeutics (NASDAQ:PSTV – Get Free Report) is anticipated to issue its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect Plus Therapeutics to announce earnings of ($0.88) per share and revenue of $1.1130 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 21, 2026 at 4:00 PM ET.
Plus Therapeutics (NASDAQ:PSTV – Get Free Report) last released its quarterly earnings data on Friday, May 15th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.20). The company had revenue of $1.03 million during the quarter, compared to the consensus estimate of $0.97 million. Plus Therapeutics had a negative net margin of 230.24% and a negative return on equity of 198.48%. On average, analysts expect Plus Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Plus Therapeutics Stock Performance
Shares of NASDAQ PSTV opened at $3.83 on Tuesday. The firm has a 50 day moving average price of $4.26 and a 200 day moving average price of $5.52. The stock has a market cap of $26.37 million, a P/E ratio of -1.67 and a beta of 1.40. Plus Therapeutics has a 52-week low of $2.90 and a 52-week high of $23.42.
Analyst Ratings Changes
Read Our Latest Analysis on Plus Therapeutics
Hedge Funds Weigh In On Plus Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in PSTV. Susquehanna International Group LLP acquired a new stake in shares of Plus Therapeutics in the third quarter valued at approximately $46,000. Jane Street Group LLC acquired a new position in Plus Therapeutics during the second quarter worth $41,000. Scientech Research LLC bought a new position in Plus Therapeutics in the third quarter valued at $100,000. XTX Topco Ltd acquired a new stake in Plus Therapeutics in the 4th quarter valued at $127,000. Finally, State Street Corp lifted its position in Plus Therapeutics by 37.1% during the 4th quarter. State Street Corp now owns 468,893 shares of the company’s stock worth $240,000 after buying an additional 127,000 shares in the last quarter. 3.28% of the stock is owned by institutional investors and hedge funds.
Plus Therapeutics Company Profile
Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.
The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.
Read More
- Five stocks we like better than Plus Therapeutics
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
